Preparation of a novel floating ring capsule-type dosage form for stomach specific delivery  by Mouzam, Md. Ismail et al.
Saudi Pharmaceutical Journal (2011) 19, 85–93King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEPreparation of a novel ﬂoating ring capsule-type dosage
form for stomach speciﬁc deliveryMd. Ismail Mouzam a,*, M.H.G. Dehghan a, Shaikh Asif b, Trupti Sahuji a,
Pooja Chudiwal aa Department of Pharmaceutical Technology, Y.B. Chavan College of Pharmacy, Dr. Babasaheb Ambedkar Marathwada University,
Aurangabad, India
b Wockhardt Research Centre, MIDC Industrial Area, Aurangabad, IndiaReceived 7 July 2010; accepted 7 January 2011
Available online 18 January 2011*
Te
C
tr
24
E
13
El
Pe
doKEYWORDS
New ﬂoating ring capsule;
Stomach speciﬁc delivery;
Polymers;
In vitro drug releaseCorresponding author. Ad
chnology, Y.B. Chavan Co
ampus, Rauza Bagh, P.O. Bo
a, India. Tel.: +91 24023813
02381129.
-mail address: mdismail1111
19-0164 ª 2011 King Saud
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.jsps.2011.01.004
Production and hdress: D
llege of P
x 33, Au
07; mobil
@rediffm
Universit
d.
y of King
osting by EAbstract Study objectives were to develop a unique ﬂoating ring capsule dosage form which
combines gastric soluble and insoluble portions, and to evaluate its suitability for stomach speciﬁc
drug delivery. New ﬂoating ring capsules were developed using different polymers and were com-
pared for various parameters. The formulation with HPMC and sodium CMC has better ﬂoating
properties. The effects of polymers concentration on drug release were studies by in vitro release
studies. The interaction studies of combined drug with polymers were determined using FT-IR
spectroscopy. The entrapped air within the gel barrier and lower densities of HPMC and sodium
CMC resulted in better ﬂoating behavior. Steady slow gel formations showed prolonged drug
release. The in vitro release rates were generally found to be faster with low concentration of car-
bopol showing release within 2 h, while formulations containing high amount of HPMC showed
release in 8 h. In particular, the higher concentration of HPMC formulation shows the best drug
release performance. A very low change in peak shift was observed only with sodium alginate for-
mulations. Further, FT-IR measurements conﬁrmed the absence of any chemical interactions.epartment of Pharmaceutical
harmacy, Dr. Raﬁq Zakaria
rangabad 431001, Maharash-
e: +91 9860440856; fax: +91
ail.com (M.I. Mouzam).
y. Production and hosting by
Saud University.
lsevier
Table 1 Studied formulations.
Code of
formulation
Sodium
alginate (mg)
Carbopo
934 (mg)
F1 100 –
F2 200
F3 100
F4 200
F5
F6
F7
F8
All the capsules formulations contain
Figure 1 Schematic drawing of the
release. (1) Filled capsule with enteri
Entrapped air and gelatin cap get dis
86 M.I. Mouzam et al.Results indicate that new ﬂoating ring capsule is a promise dosage form for stomach speciﬁc
delivery.
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During past few decades Helicobacter pylori (H. pylori) has
been recognized as a major gastric pathogen responsible for
chronic active gastritis, duodenal ulcers and gastric adenocar-
cinoma (Megraud and Lamouliatte, 1992; Forman et al.,
1994). Levoﬂoxacin hemihydrate is considered to be effective
for the treatment of H. pylori (Cavallaro et al., 2005; Enrico
et al., 2006). Oral ingestion is the predominant and most pref-
erable route for drug delivery (Chien, 1992). Always there was
interest in the development of novel capsules of hard gelatin
capsules (Sarah et al., 2010; Takashi et al., 1998). One could
envision utilizing the time-delayed systems to target relatively
speciﬁc regions of the GI tract for drug release. RingCap, a
patented technology could be an example of such develop-
ment. The intent of such technology was to provide a delivery
system with reliable and reproducible drug release characteris-
tics (Wong et al., 1996, 1997).l HPMC (mg) Sodium
CMC (mg)
– –
100
200
100
200
250 mg levoﬂoxacin.
steps involved in the drug
c body and gelatin cap. (2)
solved. (3) Drug release.Thus, it is believed that delivery of antibiotic through a
ﬂoating drug delivery system may result in incomplete removal
of the organisms in the fundal area of the gastric mucosa due
to bactericidal drug levels being reached in this area, and might
lead to better reported treatment of peptic ulcer disease (Bra-
hma et al., 2000).
Various authors report alginate and HPMC that were able
to ﬂoat on gastric contents and provided SR characteristics
(Davis et al., 1986; Muller-Lissner et al., 1981; Sheth and
Tossounian, 1984). Further Washington et al. (1986) suggested
that the formulation consists of a mixture of alginate, forms a
gel of alginic acid. The gel becomes buoyant by entrapping the
gas bubbles and ﬂoats on the gastric contents as a viscous
layer. Furthermore, cellulose ether polymers (HPMC) have a
bulk density of less than unity in gastric ﬂuids, and formula-
tion containing sodium CMC exhibited better release from
the capsules (Nathalie et al., 1997).
The aim of this study was to develop a new ﬂoating ringcap
delivery system (NFRCDS) in cross-linked hard gelatin cap-
sule shell. The effect of the preparative parameters, e.g.,
amount of the various polymers, the ﬂoating ability and drug
release properties of the NFRCDS were evaluated.
1.1. Design of dosage form
The NFRCDS was developed by ﬁrst rectiﬁcation of enteric
body and the gelatin cap. In enteric body carbopol was placed
ﬁrst and then over this circular separating ringband of 1 mm
thickness was placed. Mixture of levoﬂoxacin and polymer
were prepared as shown in Table 1 and placed over the sepa-
rating band (Fig. 1). There after gelatin cap was joined over
the enteric body. After ingestion of the capsule, the acidic envi-
ronment quickly dissolves the gelatin cap, but the enteric body
still remains intact. As a result, the formulation mixture gets
exposed to the acidic environment only from a side. This ex-
posed dry mixture gets hydrated and gradually erodes or
swells, at the same time drug dissolves in the gel and diffuses
out to the aqueous acidic environment. The deep located drug
inside the capsule body gets thrusted towards exposed acidic
environment by the separating ringband with the aid of swell-
ing carbopol polymer. This formulation does not involve gas
generation. Air is trapped inside the less dense powder bulk
drug which accounts for the buoyant behavior of the capsule.
2. Materials
Levoﬂoxacin was supplied by Wockhardt Research Ltd.
(Aurangabad, India). Hard gelatin capsules (#0) were obtained
from Concept Pharmaceuticals Ltd. (Associated Capsules,
Mumbai, India, Lot No.: DKR10387). Hydroxypropyl meth-
ylcellulose (HPMC, Lot No.: GA228766) with Mw of
100,000 and viscosity 118,567 mPa s was from Dow Chemical
Co. (Midland, MI, USA). Sodium carboxymethylcellulose (so-
dium CMC, BNo.: 61799305001046, Mw 250,000) and
4279 cP s viscosity as a 2% aqueous solution were purchased
from Merck, Mumbai (India). Sodium alginate (BNo.:
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aqueous solution were provided from LobaChemie (Mumbai,
India), and Carbopol-934 (Lot No.: 000044726) with Mw
39,400 and 501 cP s viscosity as a 2% aqueous solution were
procured from Himedia Lab Ltd. (Mumbai, India). All other
reagents used were of analytical grade. Capsule ﬁlling ma-
chines used were of ACG-Worldwide, MF-30 (Mumbai,
India).
3. Methods
3.1. Preparation of separating ringcap band
It was prepared by making 2% HMPC solution in water, fol-
lowed by the addition of 5% glycerol which was preoptimized.
Then the mixture was poured to petridish and was allowed to
dry at 45 C. The dried ﬁlm was cut uniformly into circular
rings with punch, each having 1 mm thickness and diameter
of 5.1 mm.
3.2. Preparation of enteric gelatin body
Enteric gelatin bodies were prepared by crosslinking technique
as described previously by Pina and Sousa (2002). Hard gelatin
body was separated from the cap. The formaldehyde solution
was prepared and the separated gelatin body was immersed for
15 min followed by drying.
3.3. Preparation of new ﬂoating ring capsules
Enteric gelatin bodies were ﬁlled with 50 mg powder carbopol,
then a separating ringcap band was placed. A mixture of levo-
ﬂoxacin and polymer as described in Table 1 was ﬁlled over it
with light compression and ﬁnally the capsule body was sealed
with hard gelatin cap (Fig. 2).
3.4. In vitro buoyancy studies
The in vitro buoyancy was determined by the ﬂoating time
(Rosa et al., 1994). The capsules were placed in a beaker con-
taining 100 mL of 0.1 mol L1 HCl. The ﬂoating duration of
all capsules were determined by visual observation.Figure 2 New levoﬂoxacin ﬂoating ring capsule.3.5. Infrared spectroscopic studies
The spectra were recorded on Jasco-5300 FT-IR system. Infra-
red (IR) spectroscopic analysis was carried out on the mixtures
to evaluate possible interactions between the drug and the car-
rier. Samples were prepared by KBr disc method (2 mg sample
in 200 mg KBr) and examined in the transmission mode. Indi-
vidual polymer, levoﬂoxacin and drug/polymer mixture were
run as controls. The scanning range was 400–4000 cm1 and
the resolution was 1 cm1. The recorded spectrum was sub-
jected to analysis by Essential FT-IR V 1.5 software, USA.
3.6. In vitro drug release
In vitro drug release studies were conducted using the USP
type II (paddle) dissolution apparatus (TDT-06T, Electrolab,
India). Hydrochloric acid (0.1 N) 900 mL was used as medium.
The study was conducted at 37 ± 0.5 C and at paddle rota-
tion of 50 rpm. Samples of 5 mL were collected at predeter-
mined time intervals and replaced with fresh medium. The
samples were ﬁltered and absorbance of solutions was mea-
sured at 294 nm using Shimadzu UV 1800 spectrophotometer
(Thakkar et al., 2008). The studies were performed in
triplicate.
3.7. Mathematical drug release models
The different mathematical models may be applied for describ-
ing the kinetics of the drug release process from capsules. The
kinetics of drug release from capsule formulations were deter-
mined by ﬁnding the best ﬁt of the release data to zero order,
ﬁrst order, Hixson–Crowell, Higuchi, and Korsmeyer–Peppas
plots, respectively.
3.7.1. Zero order kinetics
Drug dissolution from pharmaceutical dosage forms that do
not disaggregate and release the drug slowly (assuming that
area does not change and no equilibrium conditions are ob-
tained) is represented by
Qt ¼ Q0 þ K0t
where Qt is the amount of drug dissolved in time t, Q0 is the
initial amount of drug in the solution (most times, Q= 0)
and K0 is the zero order release constant. The exponential n
equal to 1 is considered to follow zero order kinetics (case II
transport).
3.7.2. First order kinetics
The application of this model to drug dissolution studies was
ﬁrst proposed by Gibaldi and Feldman (1967). The pharma-
ceutical dosage forms following this dissolution proﬁle, such
as those containing water-soluble drugs in porous matrices
(Mulye and Turco, 1995), release the drug in a way that is pro-
portional to the amount of drug remaining in its interior, in
such way, that the amount drug released by unit of time
diminishes:
Qt ¼ Q0 eK1t
where Qt is the amount of drug released in time t, Q0 is the ini-
tial amount of drug in the solution and K1 is the ﬁrst order re-
lease constant.
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Higuchi (1961, 1963) developed several theoretical models to
study release of high and low water soluble drugs incorporated
in the semi-solid and/or solid matrices. Higuchi describes drug
release as a diffusion process based in the Fick’s law, square
root time dependent. The simpliﬁed Higuchi’s model is given
as
Qt ¼ KHt1=2
where KH is Higuchi’s rate constant, and Qt is the amount of
drug released at time t. If a plot of square root of time vs
cumulative amount of drug released yields a straight line,
and the slope is 1 or more than 1, then the particular dosage
form is considered to follow Higuchi kinetics of drug release.
Under some experimental situations the release mechanism
deviates from the Fick’s equation, following an anomalous
behavior (non-Fickian release).
3.7.4. Korsmeyer–Peppas model
Korsmeyer et al. (1983) developed a simple, semi-empirical,
relating exponentially the drug release to the lapsed time:
Qt=Qa ¼ Ktn
where K is the constant comprising a structural and geometric
characteristics of the tablets; and n is the release exponent
indicative of the drug release mechanism, is the function of t
is Qt/Qa (fractional release of drug). Peppas (1985) used this
n value in order to characterize different release mechanisms.
If the n value is 0.5 or less, the release mechanism follows Fic-
kian diffusion controlled release, and higher valuesFigure 3 Comparison of inﬂuence of formulation variables on in
Table 2 Floating time for the various
formulations.
Code of formulation Floating time (h)
F1 2.5
F2 3.5
F3 0.75
F4 0.5
F5 5
F6 8
F7 3
F8 8(0.5 < n< 1) for mass transfer follow anomalous non-Fickian
transport mechanism.
3.7.5. Hixson–Crowell model
When this model is used, it is assumed that the release rate is
limited by the drug particles dissolution rate and not by the
diffusion that might occur through the polymeric matrix. It
is given as follows
W
1=3
0 W1=3t ¼ Kst
where W0 is the initial amount of drug, Wt is the remaining
amount of drug in dosage form at time t, and Ks is a constant
incorporating the surface volume.4. Results and discussion
4.1. In vitro buoyancy studies
The investigated model drug levoﬂoxacin has pH dependent
solubility, true density is q= 1.48 g/cm3 and the single dose
is very high, so it was a real challenge to form a ﬂoating cap-
sule which will ensure a constant drug release for a period of
8 h. The air entrapped in dense powder during ﬁlling operation
of capsules aids for the buoyancy phenomena. Sodium alginate
formulations tend to ﬂoat for lesser time, might be because of
water penetration tends to withdraw the entrapped air from
the non-compressed formulation, leading to abrupt loss of
ﬂoating strength. This result correlates with the result obtained
by Timmermans and Moes (1990). It indirectly suggests reduc-
tion in the penetration of water could lead to ﬂoating of cap-
sules for prolonged period of time. Formulations containing
HMPC and sodium CMC have better ﬂoating properties
(Table 2). This could be due to their low apparent densities
(bulk density of HPMC was 0.547 g/cm3 and for sodium
CMC 0.52 g/cm3). Higher HPMC and sodium CMC levels
were related to a lower density and thus improved ﬂoating
behavior. Further when a large amount of sodium CMC was
contained in the formulations, a part of sodium CMC located
around the capsules was rapidly dissolved to form a gel
barrier, which resulted in the entrapped air hardly being able
to escape, leading to ﬂoating of formulations (Shan-Yang
and Pei-Chin, 1992). The ﬂoating was continued over 8 h for
formulations F6 and F8, respectively.vitro drug release from new levoﬂoxacin ﬂoating ring capsules.
Figure 5 The F2 formulation containing sodium alginate after
7 h of drug release.
Figure 4 Comparison of inﬂuence of formulation variables on
in vitro drug release from new levoﬂoxacin ﬂoating ring capsules.
Preparation of a novel ﬂoating ring capsule-type dosage form for stomach speciﬁc delivery 89The formulation containing carbopol have negative effect
on ﬂoating behavior of the delivery system and the results cor-
relates with the study conducted by Shoufeng et al. (2003).
This was been explained by the moisture isotherm of carbopol,
which illustrates that carbopol has a much higher moisture
absorption curve compared to HPMC, which in turn shows
a corresponding decrease in the ﬂoating property.
4.2. Infrared spectroscopic studies
Levoﬂoxacin and the formulations were subjected to FT-IR
analysis in order to evaluate possible interactions between
the drug and the polymers. The FT-IR spectra of pure
levoﬂoxacin, drug loaded capsules are shown in Figs. 6–8.
The levoﬂoxacin FT-IR spectra obtained were similar to that
of Alex et al. (2010). The data were compared with the stan-
dard spectrum for levoﬂoxacin, and characteristic peaks asso-
ciated with speciﬁc structural characteristics of the molecule
and their presence/absence in the polymeric carrier were noted.
The peaks at 3268 and 1048 cm1 indicate the –COOH mono-
meric stretching and bonding. Two peaks at 2848 and 1620 cm
1 designate for alkanes –CH3 and aromatic rings, respectively.
Other characteristic bands are shown at 1725 cm1 for C‚O
stretching vibration of the COOH group, at 839 cm1 for C–
F peak. The spectrum of levoﬂoxacin with SA shows the peak
shift to lower frequencies for –COOH monomeric from 3268
to 3264 cm1. This peak shift could be attributed to opaque
nature, i.e., presence of moisture within the sample. All the
above peaks are present in drug-loaded formulations that con-
ﬁrm the presence of drug in the polymer without any
interaction.
4.3. In vitro drug release
Results of an in vitro drug release of levoﬂoxacin loaded cap-
sules prepared using various polymers concentrations were
shown in Figs. 3 and 4. The difference in the rate and extent
of drug release was observed in formulation F3 and F4. The
F3 formulation was characterized by a burst release, this could
be because carboxylate groups on the carbopol polymer back-
bone rapidly ionize, resulting in repulsion between the negative
particles, which adds to the swelling of the polymer and the os-
motic pressure from within which may break up the structure
(Jian, 2003), while F4 formulation showed slight delay in com-
plete drug release. This could be attributed to an increase in
tendency towards gel formation by carbopol when used in high
concentration. This suggests burst release can be reduced by
increasing the polymer concentration (Ziyaur et al., 2006).
Formulation prepared with HMPC showed better release, F6
formulation showed release upto 8 h. The photograph of
HPMC capsules suggests steady slow gel formation, which
could be the reason for prolonged release. The next best result
observed was for sodium alginate based formulations F1 and
F2. The F2 formulations showed prolonged release upto 7 h
while the F1 formulations showed release for a period of 4 h.
It has been suggested that the stability of an alginate molecule
is strongly dependent on the conditions to which it is subjected,
i.e., temperature, pH, and presence of contaminants. The gly-
cosidic linkages between the sugar monomers of the polysac-
charide are susceptible to cleavage in acidic media. If the pH
of the alginate-containing solution is lowered below the pKa
of the constituting acids, phase separation or hydrogel forma-tion occurs (Ivan and Sergio, 2009). Further becomes soluble
owing to favorable entropic contribution from the free (non-
condensed) counterions, which might result in F1 formulations
to be released with few hours, while higher concentration could
take longer bit of time for glycosidic cleavage. The shape of F2
formulation remains intact after 7 h (Fig. 5). The release pro-
ﬁle was similar to some extent for F2 and F6 formulations
might be due to more air entrapment in HPMC formulation
due to its low density, while SA formulations were compactly
packed during ﬁlling operation. It is postulated by Paolo et al.
(2000) that HPMC do not form the gel layer quickly, well be-
cause in dry systems the diffusion coefﬁcient is very low. In
such systems water acts as a plasticizer and reduces the glass
transition temperature (Tg) of the system. Once the Tg equals
the temperature of the system, the polymer chains undergo
transition from the glassy to the rubbery state (Chambina
et al., 2004). This might lead to sustained release of HPMC
formulations F5 and F6. With sodium CMC formulations,
the release was biphasic: a ﬁrst phase at the beginning of the
experiment with a slower slope and a second phase constant
until the end of the dissolution process. In comparison to
HPMC formulation, the sodium CMC formulation releases
faster, would be due to disintegrating property of sodium
90 M.I. Mouzam et al.CMC (Raymond et al., 2009). Generally drug release was ob-
served to be slower with increased polymer concentrations in
most of the formulations.
4.4. Mathematical drug release
In order to develop an ideal kinetic model to interpret in vitro
drug dissolution rate data in terms of meaningful parameters,Figure 7 FT-IR spectra of altered
Figure 6 The structural formula andvarious kinetic models were applied to obtain the best ﬁt of the
data. It has been found that the release have been realized in
accordance with zero order for F7 formulation only. Besides
the fact that it is emitted in accordance with zero order, the lev-
oﬂoxacin is distributed homogenously in the formulations. The
best ﬁt model for F1 formulation showed Peppas order release,
‘r’ values equal to 0.9825 (Table 3). The formulations F4 and
F5 showed release mechanism corresponding to Peppas modellevoﬂoxacin in SA and carbopol.
the FT-IR spectra of levoﬂoxacin.
Table 3 Some in vitro kinetic data models of prepared formulations.
Code of formulation Zero order First order Korsmeyer–Peppas Best ﬁt model
r k r k r k n
F1 0.9424 29.3616 0.8330 1.9898 0.9825 44.7911 0.6384 Peppas
F2 0.9328 11.53 0.9835 15.52 0.9548 13.47 0.96 First order
F3 0.9818 3.7739 0.9584 0.460 0.9979 0.6659 0.97 Peppas
F4 0.7112 41.9714 0.9457 2.6951 0.9982 93.2712 0.0620 Peppas
F5 0.9785 20.6659 0.6825 1.3341 0.9938 29.6334 0.7320 Peppas
F6 0.9805 9.30 0.9055 14.59 0.9836 9.35 0.99 Peppas
F7 0.9918 33.5284 0.7951 2.1658 0.9846 40.8015 0.7663 Zero order
F8 0.9833 11.43 0.9824 15.43 0.9528 13.27 0.97 Zero order
r, Correlation coefﬁcient; n, release exponent; k, kinetic constant.
Figure 8 FT-IR spectra of altered levoﬂoxacin in HPMC and sodium CMC.
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lue of the exponent n was calculated as an indicator of the drug
transport mechanism. Formulation F8 having ‘n’ values 0.97
indicates a case-II transport drug release mechanism (Siepm-
anna and Peppas, 2001). The increase in carbopol loading in
formulation F4 decreased the n value from 0.97 to 0.062. Sim-
ilar results were obtained by Aleksandra et al. (2009) for for-
mulations containing carbopol. The ‘n’ values between 0.5
and 1 have been observed for most of the formulations. This
indicates that the drug release depends on swelling, erosion,
and diffusion. The n value from the Korsmeyer–Peppas modelfor most of the formulations were between 0.6384 and 0.99
which conﬁrms the non-Fickian/anomalous type of diffusion
(Kandasamy and Veintramuthu, 2010), however, the formula-
tion containing higher concentration of carbopol followed Fic-
kian diffusion (Sam et al., 2007).
5. Conclusion
There were two principle objectives to this study. Firstly, to the
develop NFRCDS by crosslinking gelatin shell. The data pre-
sented here have established that these prepared formulations
92 M.I. Mouzam et al.were highly effective by ﬂoating phenomena in order to target
drugs to the stomach region, and to treat such H. pylori
infections.
The second objective was to assess the effects of formula-
tion variables. Such a new design may provide extended release
to improve therapeutic efﬁcacy and to provide extended resi-
dence time by ﬂoating behavior. Optimization of the ﬂoating
phenomena for such porous ﬁlled capsules can be achieved
either by slowing water penetration inside the formulation,
or by improving the swelling properties of the dosage form.
Further, these formulations were shown to be free from any
chemical interaction. The results of in vitro experiment study
demonstrated that such a new concept can be successfully ap-
plied for site speciﬁc drug delivery in the GI tract. In spite of
such a new concept, challenges will remain as there is still
scope for further optimization.Acknowledgments
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